Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma

References

• Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–967
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671–674
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Shimomura T, Naka D, Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 1994; 269: 8966–8970
   PubMed Web of Science ®Google Scholar
• van der Voort R, Taher T E, Derksen P W, Spaargaren M, van der Neut R, Pals S T. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000; 79: 39–90
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Wounde G F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915–925
   PubMed Web of Science ®Google Scholar
• Trusolino L, Comoglio P M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289–300
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029–1039
   PubMed Web of Science ®Google Scholar
• Friesel R E, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9: 919–925
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167–3172
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334–3339
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718
   PubMed Web of Science ®Google Scholar
• Hsiao L T, Lin J T, Yu I T, Chiou T J, Liu J H, Yen C C, et al. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur J Haematol 2003; 70: 282–289
   PubMed Web of Science ®Google Scholar
• Jaffe E, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• NCCN. National Comprehensive Cancer Network. The complete library of practice guidelines in oncology (online), Version 2006. Available from http://www.nccn.org
   Google Scholar
• Weidner N, Semple J P, Welch W R, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 2089–2093
   PubMed Web of Science ®Google Scholar
• Arias V, Soares F A. Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 2000; 40: 157–166
   PubMed Web of Science ®Google Scholar
• Koster A, van Krieken J HM, MacKenzie M A, Schraders M, Borm G F, van der Laak J AWM, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154–161
   PubMed Web of Science ®Google Scholar
• Ridell B, Norrby K. Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS 2001; 109: 66–72
   PubMed Web of Science ®Google Scholar
• Dammacco F, Iurlaro M, Ria R, Quondamatteo F, Nico B, Giacchetta F, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79: 965–970
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Marinelli R J, Kapp A V, Tibshirani R J, Hammer A S, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphomas subtypes. Am J Pathol 2007; 170: 1362–1369
   PubMed Web of Science ®Google Scholar
• Jorgensen J M, Sorensen F B, Bendix K, Nielsen J L, Olsen M L, Funder A M, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584–595
   PubMed Web of Science ®Google Scholar
• Giles F J, Vose J M, Do K, Johnson M M, Manshouri T, Bociek G, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004; 28: 595–604
   PubMed Web of Science ®Google Scholar
• Pedersen L M, Klausen T W, Davidsen U H, Johnsen H E. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin lymphoma. Ann Hematol 2005; 84: 510–516
   PubMed Web of Science ®Google Scholar
• Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 2002; 94: 3210–3218
   PubMed Web of Science ®Google Scholar
• Kim C H, Lee J S, Kang S O, Bae J H, Hong S P, Kahng H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol 2007; 43: 1021–1025
   PubMed Web of Science ®Google Scholar
• Eichbaum M H, de Rossi T M, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol 2007; 28: 36–44
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J-I, Nakamura S, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 68: 91–100
   PubMed Web of Science ®Google Scholar
• Aref S, Mabed M, Zalata K, Sakrana M, El Askalany H. The interplay between c-myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome. Leuk Lymphoma 2004; 45: 499–506
   PubMed Web of Science ®Google Scholar
• Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci P F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504–509
   PubMed Web of Science ®Google Scholar
• Jacob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, et al. Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42: 1581–1590
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Kay N E. The clinical and biological importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006; 33: 174–185
   PubMed Web of Science ®Google Scholar
• Kuppers R, Klein U, Hansmann M L, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341: 1520–1529
   PubMed Web of Science ®Google Scholar
• Tjin E PM, Groen R WJ, Vogelzang I, Derksen P WB, Klok M D, Meijer H P, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activation expression in diffuse large B-cell lymphoma. Blood 2006; 107: 760–768
   PubMed Web of Science ®Google Scholar
• Cao H, Björndahl M A, Gallego M I, Chen S, Religa P, Hansen A J, et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006; 107: 3531–3536
   Google Scholar
• Krause D S, Van Etten R A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172–187
   PubMed Web of Science ®Google Scholar
• Zou H Y, Li Q, Lee J H, Arango M E, McDonnell S R, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408–4417
   PubMed Web of Science ®Google Scholar
• Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66: 1721–1729
   PubMed Web of Science ®Google Scholar
• Kim K J, Wang L, Su Y C, Gillespie G Y, Salhotra A, Lal B, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006; 12: 1292–1298
   PubMed Web of Science ®Google Scholar